Recent Updates
Recently added Catalysts
ADMA Negative Sentiment Score: 25/100

ADMA FRAUD ALERT: BFA Law Notifies ADMA Biologics Investors of Ongoing Securities Fraud Investigation after Auditor Resigns and Urges You to Contact the Firm (Nasdaq:ADMA)

Key Takeaway: Bleichmar Fonti & Auld LLP has launched an investigation into ADMA Biologics for possible violations of federal securities laws following the unexpected resignation of its auditor, CohnReznick LLP. This development has triggered a sharp decline of over 20% in ADMA's stock price. Investors are encouraged to seek legal counsel and submit their information to pursue potential claims against the company. The situation poses significant risks for ADMA Biologics, as the investigation may unravel further compliance issues and legal liabilities.

Market Sentiment Analysis

CONCERNS & RISKS

  • The resignation of ADMA Biologics' independent auditor has raised concerns about potential securities fraud.
  • A significant drop in stock price (over 20%) followed the auditor's resignation, indicating negative investor sentiment.
  • The ongoing investigation could lead to legal troubles for ADMA Biologics, affecting investor confidence.

Full Press Release Details

NEW YORK, Oct. 27, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws.
If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.
Why Did ADMA Biologics’s Stock Drop?
ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, markets and develops specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.
On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.
The news has caused a precipitous decline in the price of ADMA Biologics stock. During trading on October 10, 2024, the price of ADMA Biologics stock declined more than 20%.
If you invested in ADMA Biologics you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
Attorney advertising. Past results do not guarantee future outcomes.

Tags

Frequently Asked Questions

What recent event affected ADMA Biologics's stock?

ADMA Biologics’s stock fell significantly after the unexpected resignation of its auditor.

How much did ADMA Biologics's stock decline?

On October 10, 2024, the stock dropped over 20% during trading.

What does Bleichmar Fonti & Auld LLP offer to investors?

The law firm provides legal options for investors affected by ADMA’s stock issues.

What is Bleichmar Fonti & Auld LLP known for?

It is recognized for representing plaintiffs in securities class actions and litigation.

Is there a cost for representation from BFA?

No, all representation is on a contingency fee basis, with no upfront costs.

Last updated: Oct 27, 2024